Haemonetics (HAE) Misses Q4 EPS by 5c; Guides FY16 EPS

Haemonetics (NYSE: HAE) reported Q4 EPS of $0.47, $0.05 worse than the analyst estimate of $0.52. Revenue for the quarter came in at $226.5 million versus the consensus estimate of $239.2 million.

Haemonetics sees FY2015 EPS of $1.98-$2.08, versus the consensus of $2.09.

For earnings history and earnings-related data on Haemonetics (HAE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c